Use of syngeneic monoclonal antibodies in the therapy of disseminated XXXX cells.

@entity5 @entity19 @entity2800
A syngeneic monoclonal antibody (MAb) (IC5F5) was successfully used in the immunotherapy of Rauscher-virus-induced @entity2800 RMB-I cells. It is directed to a virus-encoded, but aberrantly processed protein, which is expressed on the cell membrane. When applied in vivo, it binds only to RMB-I @entity5 cells. BALB/c @entity19 were inoculated i.p. or i.v. with 10(7) RMB-I cells and died within 2-3 weeks due to increasing @entity5 load. @entity19 inoculated i.p. were completely cured by daily injections of ascites containing IC5F5. Disseminated @entity5 cells in liver and hemopoietic organs were observed after i.v. inoculation. Daily treatment with MAbs resulted in survival beyond 90 days. No antigenic modulation was observed when @entity5 tissue was analyzed 2-10 days after treatment. Treatment was successful even when therapy was postponed until day 5 following inoculation of @entity5 cells. When the number of ascites injections was reduced, survival was identical to that observed among repeatedly treated @entity19 . Ten- and 100-fold dilution of ascites fluid diminished the number of survivors, but still resulted in a median survival time of 38 and 20 days, respectively, as compared to 14 days for untreated @entity19 .
